Cytokinetics Historical Balance Sheet

CYTK
 Stock
  

USD 52.50  1.04  1.94%   

Trend analysis of Cytokinetics balance sheet accounts such as Accounts Payable of 22.8 M, Total Assets of 907.7 M or Current Assets of 578 M provides information on Cytokinetics' total assets, liabilities, and equity, which is the actual value of Cytokinetics to its prevalent stockholders. By breaking down trends over time using Cytokinetics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year. Financial Statement Analysis is much more than just reviewing and breaking down Cytokinetics prevalent accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cytokinetics is a good buy for the upcoming year.
Continue to Trending Equities.
  

About Cytokinetics Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Cytokinetics at a specified time, usually calculated after every quarter, six months, or one year. Cytokinetics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Cytokinetics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Cytokinetics currently owns. An asset can also be divided into two categories, current and non-current.

Cytokinetics Balance Sheet Chart

Cytokinetics Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Cytokinetics uses and utilizes its capital. It also shows what exactly a company owns and owes.
Cytokinetics Current Assets are increasing as compared to previous years. The last year's value of Current Assets was reported at 535.67 Million. The current Assets Non Current is estimated to increase to about 329.8 M, while Accumulated Retained Earnings Deficit are projected to decrease to (1.2 B).

Total Assets

Total assets refers to the total amount of Cytokinetics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Cytokinetics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Major components are Cash and Equivalents; Investments; [Intangibles]; Property Plant and Equipment Net; [TaxAssets] and Trade and Non Trade Receivables.

Current Assets

Current assets of Cytokinetics include cash, cash equivalents, short-term investments, accounts receivable, stock inventory and the portion of prepaid liabilities which will be paid within a year. Depending on the nature of the business, current assets can range from barrels of crude oil, to baked goods, to foreign currency. Current assets are important because they are the assets that are used to fund day-to-day operations of Cytokinetics. The current portion of Total Assets; reported if a company operates a classified balance sheet that segments current and non-current assets.

Shareholders Equity

A principal component of the balance sheet; in addition to Total Liabilities and Total Assets; that represents the total of all stockholders' equity (deficit) items; net of receivables from officers; directors; owners; and affiliates of the entity which are attributable to the parent.

Total Liabilities

Deferred Income Tax is recorded on Cytokinetics balance sheet and a result of income already earned and recognized for accounting, but not tax, purposes. Also, differences between tax laws and accounting methods can result in a temporary difference in the amount of income tax payable by a company. This difference is recorded on Cytokinetics books as deferred income tax. Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Principal components are Total Debt; Deferred Revenue; Trade and Non Trade Payables; Deposit Liabilities; and Tax Liabilities.
Most accounts from Cytokinetics balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Cytokinetics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Continue to Trending Equities.Cytokinetics Current Assets are increasing as compared to previous years. The last year's value of Current Assets was reported at 535.67 Million. The current Assets Non Current is estimated to increase to about 329.8 M, while Accumulated Retained Earnings Deficit are projected to decrease to (1.2 B).
 2019 2020 2021 2022 (projected)
Accounts Payable8.16 M8.05 M21.09 M22.75 M
Receivables5.16 M4.42 M51.82 M55.91 M

Cytokinetics balance sheet Correlations

0.960.910.810.990.540.920.980.920.690.890.850.760.970.860.890.850.961.00.82
0.960.970.910.980.650.980.980.980.80.850.940.870.980.950.930.941.00.970.74
0.910.970.980.950.720.970.920.970.840.860.990.950.950.980.910.980.970.920.73
0.810.910.980.860.770.930.840.930.860.80.990.980.880.980.870.980.910.830.65
0.990.980.950.860.590.960.980.960.740.880.90.810.980.910.910.890.981.00.8
0.540.650.720.770.590.60.580.590.460.680.680.680.590.690.740.680.650.560.34
0.920.980.970.930.960.60.941.00.870.780.970.920.960.980.880.970.980.930.73
0.980.980.920.840.980.580.940.930.730.860.870.780.970.880.930.860.980.980.82
0.920.980.970.930.960.591.00.930.870.770.970.920.960.980.870.970.980.930.72
0.690.80.840.860.740.460.870.730.870.480.890.890.830.910.690.920.80.70.57
0.890.850.860.80.880.680.780.860.770.480.780.710.820.760.870.730.850.90.79
0.850.940.990.990.90.680.970.870.970.890.780.990.920.990.850.990.940.860.66
0.760.870.950.980.810.680.920.780.920.890.710.990.850.970.790.980.870.770.57
0.970.980.950.880.980.590.960.970.960.830.820.920.850.940.890.930.980.970.77
0.860.950.980.980.910.690.980.880.980.910.760.990.970.940.871.00.950.870.66
0.890.930.910.870.910.740.880.930.870.690.870.850.790.890.870.840.930.90.75
0.850.940.980.980.890.680.970.860.970.920.730.990.980.931.00.840.940.860.65
0.961.00.970.910.980.650.980.980.980.80.850.940.870.980.950.930.940.970.74
1.00.970.920.831.00.560.930.980.930.70.90.860.770.970.870.90.860.970.82
0.820.740.730.650.80.340.730.820.720.570.790.660.570.770.660.750.650.740.82
Click cells to compare fundamentals

Cytokinetics Account Relationship Matchups

Cytokinetics balance sheet Accounts

201720182019202020212022 (projected)
Accounts Payable5.25 M3.76 M8.16 M8.05 M21.09 M22.75 M
Accumulated Other Comprehensive Income137 K343 K500 K679 K(869 K)(891.87 K)
Total Assets294.81 M211.18 M289.81 M533.8 M841.32 M907.74 M
Current Assets274.3 M207.67 M233.75 M474.22 M535.67 M577.96 M
Assets Non Current20.52 M3.5 M56.06 M59.58 M305.65 M329.78 M
Cash and Equivalents125.21 M42.26 M36.43 M82.98 M112.67 M91.18 M
Cash and Equivalents USD125.21 M42.26 M36.43 M82.98 M112.67 M91.18 M
Total Debt31.78 M43.18 M136.07 M138.94 M269.93 M291.24 M
Debt Non Current31.78 M40.58 M131.45 M136.15 M255.07 M275.2 M
Total Debt USD31.78 M43.18 M136.07 M138.94 M269.93 M291.24 M
Deferred Revenue20.86 M23.06 M24.57 M87 M100.05 M107.95 M
Shareholders Equity109.84 M25.93 M(10.94 M)113.38 M243.86 M263.12 M
Shareholders Equity USD109.84 M25.93 M(10.94 M)113.38 M243.86 M263.12 M
Investments160.2 M156.47 M231.33 M418.03 M511.02 M551.37 M
Investments Current143.69 M156.47 M188.68 M381.07 M358.97 M387.31 M
Investments Non Current7.67 M16.52 M42.65 M36.95 M152.05 M164.05 M
Total Liabilities184.97 M185.24 M300.75 M420.42 M597.46 M644.62 M
Current Liabilities32.44 M22.19 M26.02 M31.2 M71.86 M77.53 M
Liabilities Non Current152.52 M163.05 M274.73 M389.22 M525.6 M567.09 M
Trade and Non Trade Payables5.25 M3.76 M8.16 M8.05 M21.09 M22.75 M
Property Plant and Equipment Net3.57 M3.5 M13.41 M16.27 M146.41 M157.97 M
Trade and Non Trade Receivables1.11 M2.23 M5.16 M4.42 M51.82 M55.91 M
Accumulated Retained Earnings Deficit(646.08 M)(743.32 M)(865.02 M)(992.31 M)(1.21 B)(1.24 B)

Be your own money manager

Our tools can tell you how much better you can do entering a position in Cytokinetics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Rebalancing Now

   

Portfolio Rebalancing

Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
All  Next Launch Module

Pair Trading with Cytokinetics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytokinetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytokinetics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Cytokinetics

0.7BLUBellus Health Earnings Call  TodayPairCorr
The ability to find closely correlated positions to Cytokinetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytokinetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytokinetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytokinetics to buy it.
The correlation of Cytokinetics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytokinetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytokinetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytokinetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
4.4 B
Quarterly Revenue Growth YOY
30.29
Return On Assets
-0.17
Return On Equity
-3.38
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.